KRASG12C

Overview

KRASG12C refers to a specific oncogenic variant of the KRAS gene, defined by a glycine-to-cysteine substitution at codon 12. This mutation is clinically important because it creates a druggable cysteine residue that has enabled the development of mutation-selective KRAS inhibitors. In cancer biology, KRASG12C is most prominently associated with solid tumors such as non-small-cell lung cancer (NSCLC) and lung adenocarcinoma (LUAD), and it is also relevant in pancreatic cancer research.

Biologically, KRAS is a central signaling node that regulates pathways involved in cell growth and survival, including downstream MAPK signaling. In KRASG12C-mutant tumors, constitutive oncogenic signaling drives malignant proliferation and therapeutic resistance. The emergence of KRASG12C inhibitors has represented a major advance in targeted oncology, but resistance remains a significant challenge, motivating ongoing research into combination strategies and resistance mechanisms involving pathways such as FGF2-PI3K-Akt1 signaling and MAPK1-related signaling outputs.

Focus of Latest Publications

Recent publications on KRASG12C have focused on both direct targeting of the mutant protein and strategies to overcome resistance. A conference review highlighted irreversible KRASG12C inhibitors as a notable therapeutic advance in oncology, reflecting continued interest in this target. In parallel, preclinical and translational studies have examined how KRASG12C-directed therapies can be paired with other approaches to improve efficacy and durability of response.

Several studies addressed resistance mechanisms to KRASG12C inhibition. One report identified ATF3-mediated asparagine biosynthesis as a key driver of acquired resistance, showing that chronic activation of the integrated stress response upregulated ATF3 and ASNS, and that genetic suppression of ATF3 or ASNS restored sensitivity to KRASG12C inhibitors. Exogenous asparagine re-established resistance, and pharmacologic inhibition of PERK synergized with KRASG12C inhibition to overcome resistance. Another clinical study of glecirasib (JAB-21822) in patients with advanced KRASG12C-mutant solid tumors found that circulating tumor cell dynamics tracked treatment response and progression, with changes in epithelial, mesenchymal, and mixed CTC subtypes associated with survival outcomes and resistance. Baseline CTC burden also correlated with shorter progression-free survival, suggesting a potential biomarker approach for monitoring KRASG12C-targeted therapy.

Other publications explored combination and alternative targeting strategies involving KRASG12C. Structure-based drug design yielded potent and selective SOS1 inhibitors that disrupted the SOS1-KRASG12C interaction, inhibited nucleotide exchange, suppressed MAPK and PI3K signaling, and showed antitumor activity in colorectal cancer models. A separate active fragment assembly study identified a Kras inhibitor with activity in pancreatic cancer cell lines harboring KRASG12C and KRASG12D mutations, with downstream suppression of phosphorylated Raf1, AKT, and ERK. Together, these studies suggest that KRASG12C remains a central therapeutic target, with current research emphasizing resistance biology, biomarker-guided treatment, and combination strategies that extend beyond direct inhibition.

Key Publications

• NEWJul Forging New Pathways in Oncology: Strategic Insights from the 17th Annual Frontiers in Cancer Science Conference. (Cancer research, 2026, PMID 42388021): "Breakthroughs in therapeutic engineering were showcased, including CD7-directed chimeric antigen receptor T cells and irreversible KRASG12C inhibitors."
• NEWJul The dynamic evolution of circulating tumor cells during glecirasib treatment predicts survival and resistance in gastrointestinal tumors with KRASG12C mutation. (Human cell, 2026, PMID 42384131): "Long considered an undruggable target, KRAS has recently become actionable with the development of direct inhibitors, particularly against the G12C mutation."
• NEWJun Targeting ATF3-mediated asparagine biosynthesis reverses acquired resistance to KRASG12C inhibitors. (Oncogene, 2026, PMID 42270775): "Despite substantial advances in targeting KRASG12C, tumor acquired resistance to KRASG12C inhibitors (KRASG12Ci) remains a major barrier to progress."
• Jun Discovery of Highly Potent and Selective SOS1 Inhibitors for the Treatment of KRAS-Driven Colorectal Cancer. (Journal of medicinal chemistry, 2026, PMID 42247371): "This effort yielded highly potent and selective SOS1 inhibitors, 78b and 78d, which displayed high SOS1 binding affinity, potently disrupted the SOS1-KRASG12C interaction, and inhibited nucleotide exchange in WT and multiple KRAS variants."
• May Targeted KRASG12V Degradation in vivo Elicits Lung Adenocarcinoma Regression with Subsequent Relapse from Dysregulated Proteolysis. (Cancer research, 2026, PMID 42200804): "Recent drug discovery breakthroughs led to the approval of KRASG12C inhibitors in lung adenocarcinoma (LUAD)."
• Jun Active fragment assembly strategy enabling fast discovery of KRAS inhibitors against pancreatic cancer cells. (European journal of medicinal chemistry, 2026, PMID 41931988): "Preliminary assessments indicate that compound 10b exhibits significant inhibitory activity in pancreatic cancer cells harboring KRASG12C and KRASG12D mutations."